

## DESCRIPTION

<b>Source</b>	Mouse myeloma cell line, NS0-derived Gln382-His513 Accession # P22004
<b>N-terminal Sequence Analysis</b>	No results obtained. Gln382 expected
<b>Structure / Form</b>	Disulfide-linked homodimer, biotinylated via sugars
<b>Predicted Molecular Mass</b>	15 kDa (unlabeled)

## SPECIFICATIONS

<b>Activity</b>	Measured by its ability to induce alkaline phosphatase production by ATDC5 mouse chondrogenic cells. Nakamura, K. <i>et al.</i> (1999) <i>Exp. Cell Res.</i> <b>250</b> :351. The ED <sub>50</sub> for this effect is typically 0.02-0.15 µg/mL.
<b>Endotoxin Level</b>	<0.10 EU per 1 µg of the protein by the LAL method.
<b>Purity</b>	>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
<b>Formulation</b>	Lyophilized from a 0.2 µm filtered solution in HCl. See Certificate of Analysis for details.

## PREPARATION AND STORAGE

<b>Reconstitution</b>	Reconstitute at 100 µg/mL in 4 mM HCl.
<b>Shipping</b>	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
<b>Stability &amp; Storage</b>	<b>Use a manual defrost freezer and avoid repeated freeze-thaw cycles.</b> <ul style="list-style-type: none"> <li>● 12 months from date of receipt, -20 to -70 °C as supplied.</li> <li>● 1 month, 2 to 8 °C under sterile conditions after reconstitution.</li> <li>● 3 months, -20 to -70 °C under sterile conditions after reconstitution.</li> </ul>

## BACKGROUND

Bone Morphogenetic Protein 6 (BMP-6), also known as Vgr-1, is a member of the BMP subfamily of TGF-β superfamily proteins. BMPs are involved in a wide range of processes including embryogenesis, tissue morphogenesis, cell differentiation and migration, and tumorigenesis (1). Human BMP-6 is synthesized as a 513 amino acid (aa) precursor protein that is cleaved at the dibasic cleavage site (RxxR) to release the 18 kDa C-terminal mature protein. Biologically active BMP-6 consists of a disulfide-linked homodimer of the mature protein, although it can also form heterodimers with mature BMP-2 (2, 3). Mature human BMP-6 shares 96% and 98% aa sequence identity with mouse and rat BMP-6, respectively. Cellular responses to BMP-6 are mediated by hetero-oligomeric complexes of type I (Activin RIA/ALK-2 and BMPR-IA/ALK-3) and type II (Activin RIIA and BMPR-II) serine/threonine kinase receptors (4, 5). BMP-6 induces the expression of Noggin and is subsequently antagonized by Noggin (6). BMP-6 induces a wide range of cellular responses. It promotes osteoblast differentiation from mesenchymal stem cells (7), chondrocyte maturation (8), Ang II-induced aldosterone production in the adrenal cortex (4), hormone production and responsiveness in ovarian granulosa cells (9), iNOS and TNF-α production in macrophages (5), the cell death of B cells (10), and neurite outgrowth (11). BMP-6 expression is induced in astrocytes surrounding sites of brain injury where it functions as a neuroprotectant (11, 12). It enhances tumor progression by promoting local angiogenesis and differentiation of immune tolerizing M2 macrophages (13-15). Through interactions with the BMP co-receptor RGM-C/Hemojuvelin, BMP-6 plays an important role in iron homeostasis by promoting Hepcidin expression and preventing serum iron overload (16). Heterodimers of BMP-2 and BMP-6 show increased potency at inducing osteoblastic calcium deposition, chondrogenesis, and *in vivo* bone formation compared to either BMP-2 or BMP-6 homodimers (3).

### References:

1. Bragdon, B. *et al.* (2010) *Cell Signal.* **23**:609.
2. Celeste, A.J. *et al.* (1990) *Proc. Natl. Acad. Sci. USA* **87**:9843.
3. Israel, D.I. *et al.* (1996) *Growth Factors* **13**:291.
4. Inagaki, K. *et al.* (2006) *Endocrinology* **147**:2681.
5. Hong, J.H. *et al.* (2008) *Immunology* **128**:e442.
6. Haudenschild, D.R. *et al.* (2004) *Cancer Res.* **64**:8276.
7. Lavery, K. *et al.* (2008) *J. Biol. Chem.* **283**:20948.
8. Grimsrud, C.D. *et al.* (1999) *J. Bone Miner. Res.* **14**:475.
9. Shi, J. *et al.* (2009) *Fertil. Steril.* **92**:1794.
10. Kersten, C. *et al.* (2005) *BMC Immunol.* **6**:9.
11. Yabe, T. *et al.* (2002) *J. Neurosci. Res.* **68**:161.
12. Zhang, Z. *et al.* (2006) *Neuroscience* **138**:47.
13. Dai, J. *et al.* (2005) *Cancer Res.* **65**:8274.
14. Kwon, S.J. *et al.* (2014) *Prostate* **74**:121.
15. Lee, J.-H. *et al.* (2013) *Cancer Res.* **73**:3604.
16. Andriopoulos, B. Jr. *et al.* (2009) *Nat. Genet.* **41**:482.